Peritoneal Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

When malignant cells invade the serous membrane lining the abdominal cavity, viscera, or coelom in amniotes, this condition is referred to as peritoneal surface malignancy, also known as peritoneal cancer (PC). Primary and secondary varieties are available. Peritoneal cancer is the term used to describe the invasion of cancerous cells into the serous membrane lining the abdominal cavity, viscera, and coelom in amniotes. A cancer called primary mesothelioma arises exclusively from the abdominal mesothelium. Peritoneal tumors are uncommon, advanced cancers of the human body. The incidence rate of primary peritoneal cancer, adjusted for age, is 6.78 per million.

Description

The invasion of malignant cells into the serous membrane lining the abdominal cavity, viscera, and coelom in amniotes is referred to as peritoneal surface malignancy or peritoneal cancer (PC). It comes in primary and secondary varieties. In the abdominal mesothelium, primary mesothelioma is a malignancy that starts from nothing. However, secondary peritoneal cancer arises when tumor cells from other sites invade the peritoneal cavity. On the basis of histology, researchers have classified primary cancer. Extraovarian Mullerian adenocarcinoma, serous surface papillary carcinoma, papillary serous carcinoma of the peritoneum, and normal-sized ovarian cancer syndrome are a few names for the first type.

Peritoneal Cancer (Epidemiology)

Peritoneal tumors are a rare, advanced form of cancer in humans. The incidence rate of primary peritoneal cancer, adjusted for age, is 6.78 per million. White people have the highest rate while Black people have the lowest rate. The most typical histological type of primary peritoneal cancer accounts for 10% of cancers in the pelvis: serous carcinoma of the peritoneum. A less frequent but incredibly deadly cancer is malignant mesothelioma. Peritoneal mesothelioma (MPM), followed by pleural mesothelioma, is the most prevalent type of mesothelioma. MPM is present in 10 to 15% of mesothelioma cases. About half of leiomyosarcomas are located in the retroperitoneum. Peritoneal cancers are all very uncommon, with an age-adjusted incidence of 0.65 per 100,000 women in the United States. Extremely few people develop primary peritoneal cancer. In the United States, 600 new cases of malignant peritoneal mesothelioma are diagnosed each year, making up 10 to 15% of all cases of the condition. Rare tumors like primary peritoneal carcinoma almost exclusively affect women. Malignant mesotheliomas have a 93% male incidence in one series. Desmoplastic small round cell tumors can appear in adolescents and young men. Despite claims that epithelial ovarian cancers tend to affect older patients more frequently than primary peritoneal carcinomas, a study from the United Kingdom found no statistically significant difference in age between the two groups (mean 64.43 vs 64.07 years, respectively P=0.9). In general, benign cystic peritoneal mesotheliomas are uncommon and more common in younger women. Most cases of leiomyomatosis peritonealis disseminata are found in women who are in their reproductive years (mean age 37 years), in young mothers, and in women who have hormonal excess for any other reason. In most cases, nodules either regress or grow when hormonal stimulation is stopped.

Peritoneal Cancer -Current Market Size & Forecast Trends

The market for peritoneal cancer is expected to grow significantly, with projections indicating a value of approximately USD 5.9 billion in 2024, anticipated to reach around USD 15.9 billion by 2031, reflecting a compound annual growth rate (CAGR) of 18.2% during the forecast period from 2024 to 2034. This growth is driven by advancements in treatment options such as targeted therapies, immunotherapies, and Hyperthermic Intraperitoneal Chemotherapy (HIPEC), which allows for high drug concentrations directly in the peritoneal cavity. The increasing prevalence of peritoneal cancer, along with improvements in genetic profiling and biomarker identification for early diagnosis, further supports market expansion. The United States is projected to have the largest patient pool and market share, attributed to ongoing research and the development of new therapeutic drugs. Overall, the peritoneal cancer market is well-positioned for substantial growth through 2035 as innovative treatment strategies continue to evolve.

When malignant cells invade the serous membrane that lines the abdominal cavity, the viscera, or the coelom in amniotes, it is referred to as peritoneal cancer. A cancer called primary mesothelioma arises exclusively from the abdominal mesothelium. Secondary peritoneal cancer, on the other hand, happens when tumor cells from other places in the body migrate to the peritoneal cavity. In addition to these names, the first type is also referred to as extraovarian Mullerian adenocarcinoma, papillary serous peritoneal carcinoma, extraovarian primary peritoneal carcinoma (EOPPC), serous surface papillary carcinoma, and normal-sized ovarian carcinoma syndrome. Other types include leiomyosarcomas, leiomyomatosis peritonealis disseminata, multicystic mesothelioma, desmoplastic small round cells tumor (DSRCT), and malignant small round cells tumor (MPM). The best therapeutic approach for peritoneal cancer is multimodal therapy. Surgery, chemotherapy, and targeted therapy are the mainstays of treatment. Both systemic and intraperitoneal chemotherapy are methods of cancer treatment. EOPPC is treated similarly to serous ovarian carcinomas. Hysterectomy, bilateral salpingo-oophorectomy, and omentectomy are always carried out in addition to each other. Then, chemotherapy and targeted therapy are applied using poly (ADP-ribose) polymerase (PARP) inhibitors, which stop DNA repair. Olaparib, rucaparib, niraparib, or veliparib are among the drugs it contains. Chemotherapy based on platinum is used in neoadjuvant therapy because it is efficient. Intraperitoneal chemotherapy (IPC) and cytoreductive surgery are considered the first lines of treatment for MPM. Early postoperative chemotherapy (EPIC) is not preferred by the information gathered over heated intraperitoneal chemotherapy (HIPEC). The primary management strategy for DSRCT is neoadjuvant chemotherapy. The tumor is aggressively surgically removed after systemic chemotherapy using the P6 protocol, which consists of cyclophosphamide, ifosfamide, vincristine, etoposide, doxorubicin, and mesna. Additionally, new non-invasive detection methods for peritoneal cancer should be developed, such as liquid biopsy (serum and ascitic fluid), which contains biomarkers made up of "exosomes," which protect cancer cells from deterioration.

Report Highlights

Peritoneal Cancer - Current Market Trends

Peritoneal Cancer - Current & Forecasted Cases across the G8 Countries

Peritoneal Cancer - Market Opportunities and Sales Potential for Agents

Peritoneal Cancer - Patient-based Market Forecast to 2035

Peritoneal Cancer - Untapped Business Opportunities

Peritoneal Cancer - Product Positioning Vis-a-vis Competitors' Products

Peritoneal Cancer - KOLs Insight